Autonomic Nervous System Drugs Practice Questions

Q: The regional aerial resistance of the mesentery and kidney is reduced by:

Dopamine. **Explanation:** The correct answer is **Dopamine**. This is due to its unique dose-dependent receptor activity. At low doses (0.5–2 µg/kg/min), dopamine primarily acts on **D1 receptors** located in the renal, mesenteric, coronary, and cerebral vascular beds. Activation of these Gs-protein-coupled receptors increases intracellular cAMP, leading to potent vasodilation. This reduces regional vascular resistance and increases blood flow to the kidneys (promoting diuresis) and the mesentery. **Why the other options are incorrect:** * **Noradrenaline:** It is a potent α1, α2, and β1 agonist with negligible β2 or D1 activity. It causes intense systemic vasoconstriction, which **increases** vascular resistance in the renal and mesenteric beds. * **Adrenaline:** While it has β2-mediated vasodilatory effects in skeletal muscle at low doses, its α1-mediated vasoconstrictive effects predominate in the renal and mesenteric vasculature, typically **increasing** resistance. * **Isoprenaline:** A pure β1 and β2 agonist. While it causes systemic vasodilation (reducing peripheral resistance in skeletal muscles), it does not have specific D1-mediated action on the mesenteric or renal beds to the same extent as dopamine. **High-Yield Clinical Pearls for NEET-PG:** * **Dopamine Dose-Response:** * *Low Dose (D1):* Renal/Mesenteric vasodilation ("Renal dose"). * *Medium Dose (β1):* Positive inotropic effect (increases Cardiac Output). * *High Dose (α1):* Systemic vasoconstriction (increases BP). * **Fenoldopam:** A selective D1 agonist used in hypertensive emergencies to maintain renal perfusion. * **Drug of Choice:** While dopamine increases renal blood flow, it has not been proven to prevent acute renal failure; **Norepinephrine** is currently the preferred vasopressor in septic shock.

Q: Neostigmine antagonizes non-depolarizing blockade by all of the following mechanisms EXCEPT:

Preventing the K+ efflux from the cell. **Explanation:** Neostigmine is a reversible acetylcholinesterase (AChE) inhibitor used clinically to reverse the effects of non-depolarizing neuromuscular blockers (NDNMBs) like vecuronium or rocuronium. Its primary mechanism involves increasing the concentration of acetylcholine (ACh) at the neuromuscular junction to outcompete the blocker. **Why Option B is Correct:** Neostigmine does **not** prevent K+ efflux from the cell. Potassium efflux is a physiological process involved in the repolarization phase of an action potential. Neostigmine’s actions are centered on modulating ACh levels and direct nicotinic receptor stimulation, rather than altering ion channel kinetics related to potassium. **Analysis of Incorrect Options:** * **Option A:** This is the primary mechanism. By inhibiting AChE, neostigmine prevents the hydrolysis of ACh, increasing its availability at the motor end plate to displace the NDNMB. * **Option C:** Neostigmine has a secondary "presynaptic" effect where it promotes the mobilization and release of more ACh vesicles from the motor nerve terminal. * **Option D:** Neostigmine (and other carbamates) possesses a direct agonistic action on nicotinic receptors ($N_m$), causing direct depolarization of the motor end plate. **NEET-PG High-Yield Pearls:** * **Co-administration:** Neostigmine is always given with an antimuscarinic (usually **Glycopyrrolate**) to prevent bradycardia and excessive secretions caused by systemic ACh accumulation. * **Quaternary Ammonium:** Neostigmine is a polar quaternary ammonium compound; it does **not** cross the blood-brain barrier (unlike Physostigmine). * **Ceiling Effect:** Neostigmine has a "ceiling effect" for reversal; if the blockade is too intense, increasing the dose will not provide further antagonism and may lead to a cholinergic crisis.

Q: The use of succinylcholine is not contraindicated in which of the following conditions?

Hepatic failure. **Explanation:** The core concept behind the contraindications of **Succinylcholine (SCh)**, a depolarizing neuromuscular blocker, is its tendency to cause **hyperkalemia** and increase **intracranial pressure (ICP)**. **Why Hepatic Failure is the Correct Answer:** Succinylcholine is metabolized by **pseudocholinesterase** (plasma cholinesterase), which is synthesized in the liver. In hepatic failure, levels of this enzyme may be low, leading to a **prolonged duration of action** (apnea). However, this is a *precaution* rather than an absolute contraindication. SCh does not worsen the underlying liver disease, nor does liver disease trigger the life-threatening hyperkalemic response seen in the other options. **Why the other options are Incorrect:** * **Tetanus & Cerebral Stroke (C):** These conditions involve upper motor neuron lesions or prolonged immobilization. This leads to the **upregulation of extrajunctional nicotinic receptors**. When SCh acts on these receptors, it causes massive potassium release from muscles, leading to severe, potentially fatal **hyperkalemia** and cardiac arrest. * **Closed Head Injury (B):** SCh causes fasciculations that can increase **intracranial pressure (ICP)** and intraocular pressure. In a head injury where ICP is already compromised, SCh is generally avoided to prevent secondary brain injury. **NEET-PG High-Yield Pearls:** 1. **Drug of Choice:** SCh is the drug of choice for **Rapid Sequence Induction (RSI)** due to its fastest onset (30-60s) and shortest duration (5-10 mins). 2. **Malignant Hyperthermia:** SCh is a notorious trigger; the antidote is **Dantrolene**. 3. **Phase II Block:** Occurs with high doses or continuous infusion, where the block behaves like a non-depolarizing one. 4. **Genetic Variation:** Patients with atypical pseudocholinesterase (detected by **Dibucaine number**) experience prolonged paralysis after SCh administration.

Q: Therapeutic use of acetylcholine is not possible because it is -

Rapidly degraded. **Explanation:** Acetylcholine (ACh) is the primary neurotransmitter of the parasympathetic nervous system, but it has **no clinical therapeutic utility** primarily because it is **rapidly degraded**. **1. Why "Rapidly Degraded" is correct:** ACh is a substrate for two major enzymes: **Acetylcholinesterase (AChE)**, found at synaptic clefts, and **Butyrylcholinesterase (Pseudocholinesterase)**, found in the plasma and liver. These enzymes hydrolyze ACh within milliseconds of administration. Consequently, even when given intravenously, it cannot reach target receptors in sufficient concentrations or for a long enough duration to produce a meaningful clinical effect. Furthermore, it lacks receptor selectivity, acting on both Muscarinic and Nicotinic receptors throughout the body. **2. Why other options are incorrect:** * **Highly protein bound:** ACh is a small, polar quaternary ammonium compound; it does not show significant plasma protein binding. * **Rapidly excreted:** While it is cleared quickly, the rate-limiting step for its inactivity is metabolic hydrolysis, not renal excretion. * **Orally ineffective:** While true (it is destroyed by gastric acid and esterases in the gut), this is not the primary reason it isn't used. Even if given parenterally, its rapid degradation in the blood renders it useless. **High-Yield Clinical Pearls for NEET-PG:** * **Synthetic Analogs:** To overcome rapid degradation, synthetic choline esters like **Bethanechol** and **Carbachol** were developed. They are resistant to AChE and have a longer duration of action. * **Miochol-E:** A stabilized form of ACh is used intraocularly *only* during ophthalmic surgery (e.g., cataract surgery) for immediate miosis, as it can be applied directly to the site of action. * **Structure:** ACh is a quaternary ammonium compound, meaning it is permanently charged and **cannot cross the Blood-Brain Barrier (BBB)**.

Q: Botulinum toxin mimics which class of drugs?

Anticholinergics. **Explanation:**1. Why Anticholinergics is the correct answer:Botulinum toxin (produced by *Clostridium botulinum*) acts by cleaving **SNARE proteins** (specifically SNAP-25, synaptobrevin, or syntaxin) at the presynaptic nerve terminal. This prevents the fusion of synaptic vesicles with the presynaptic membrane, thereby **inhibiting the release of Acetylcholine (ACh)** into the synaptic cleft [1]. Since it blocks cholinergic transmission at both the neuromuscular junction (NMJ) and autonomic ganglia/parasympathetic endings, it results in effects similar to **Anticholinergics** (e.g., muscle paralysis, dry mouth, and blurred vision) [2, 3].2. Why other options are incorrect:* **Cholinergics:** These drugs (e.g., Pilocarpine, Neostigmine) enhance or mimic ACh action. Botulinum toxin does the opposite by preventing ACh release.* **Adrenergics:** These drugs act on the sympathetic nervous system (Norepinephrine/Epinephrine). Botulinum toxin specifically targets cholinergic vesicles.* **Antiadrenergics:** These drugs (e.g., Beta-blockers) inhibit sympathetic activity. While Botulinum toxin is an inhibitor, its site of action is the cholinergic system, not the adrenergic system.3. NEET-PG High-Yield Pearls:* **Mechanism:** Irreversible inhibition of ACh release (Presynaptic blockade).* **Clinical Uses:** Strabismus, Blepharospasm, Achalasia Cardia, Spasticity, Hyperhidrosis, and Cosmetic (Botox) for wrinkles.* **Antidote for Botulism:** Equine Botulinum Antitoxin (Heptavalent).* **Comparison:** **Black Widow Spider Venom (Latrotoxin)** does the opposite—it causes massive explosive release of ACh, leading to muscle spasms.

Q: Which of the following is an example of a long-acting neuromuscular blocker?

Pancuronium. **Explanation:** Neuromuscular blocking agents (NMBAs) are classified based on their chemical structure and, more clinically relevant for the NEET-PG, their **duration of action**. **1. Why Pancuronium is Correct:** **Pancuronium** is a long-acting, non-depolarizing steroid-based NMBA. It typically has a duration of action exceeding **60–90 minutes**. It is primarily excreted by the kidneys, meaning its action is significantly prolonged in patients with renal failure. **2. Analysis of Incorrect Options:** * **Rocuronium (Option A):** An intermediate-acting steroid derivative. It is highly high-yield because it has the **fastest onset of action** (60–90 seconds) among non-depolarizing blockers, making it an alternative to Succinylcholine for Rapid Sequence Induction (RSI). * **Vecuronium (Option B):** An intermediate-acting steroid derivative (duration ~30–40 minutes). It is noted for its cardiovascular stability. * **Atracurium (Option D):** An intermediate-acting benzylisoquinoline. It is unique because it undergoes **Hofmann elimination** (spontaneous degradation in plasma), making it the drug of choice in patients with liver or kidney failure. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Long-acting:** "Pipe and Pan" (**Pipecuronium** and **Pancuronium**). * **Vagolytic Effect:** Pancuronium causes tachycardia by blocking muscarinic receptors in the heart; avoid in patients where tachycardia is detrimental. * **Drug of Choice in Renal/Hepatic Failure:** Atracurium or **Cisatracurium** (Cisatracurium is more potent and produces less histamine). * **Shortest Acting NMBA:** **Succinylcholine** (Depolarizing) or **Gantacurium** (Non-depolarizing, ultra-short). * **Reversal Agent:** Sugammadex is specifically used to reverse steroid-based NMBAs (Rocuronium > Vecuronium > Pancuronium).

Q: Which of the following drugs exhibits the phenomenon described?

Ephedrine. ***Ephedrine*** - **Indirect sympathomimetic** that depletes **norepinephrine stores** from nerve terminals, leading to **tachyphylaxis**. - With repeated doses, the response progressively **decreases** as the NE stores become **depleted**. *Epinephrine* - **Direct-acting** sympathomimetic that directly stimulates **adrenergic receptors**. - Does **not exhibit tachyphylaxis** as it doesn't depend on endogenous neurotransmitter stores. *Dopamine* - Has **mixed mechanism** (direct and indirect) but does not show **classic tachyphylaxis**. - At therapeutic doses, primarily acts as a **direct agonist** at dopaminergic and adrenergic receptors. *Isoprenaline* - **Direct β-adrenergic agonist** that acts directly on **β1 and β2 receptors**. - Shows **no tachyphylaxis** as it doesn't rely on endogenous catecholamine release.

Question 1

A gardener was accidentally poisoned by a weed killer that inhibits acetylcholinesterase. Which of the following alterations in neurochemical transmission at brain cholinergic synapses is the most likely result of this poisoning?

Accepted Answer

A pileup of acetylcholine outside the cholinergic neuron in the synaptic cleft

Answer

Blockade of cholinergic receptors

Answer

A pileup of choline outside the cholinergic neuron in the synaptic cleft

Answer

Up-regulation of postsynaptic cholinergic receptors

Question 2

The regional aerial resistance of the mesentery and kidney is reduced by:

Accepted Answer

Dopamine

Answer

Noradrenaline

Answer

Adrenaline

Answer

Isoprenaline

Question 3

Neostigmine antagonizes non-depolarizing blockade by all of the following mechanisms EXCEPT:

Accepted Answer

Preventing the K+ efflux from the cell

Answer

Decreasing the breakdown of acetylcholine at the motor end plate

Answer

Increasing the release of acetylcholine at the motor end plate

Answer

Depolarization at the motor end plate

Question 4

What is the action of alpha 2 and beta 1 receptors on adenyl cyclase?

Accepted Answer

Inhibit; Stimulate

Answer

Stimulate; Stimulate

Answer

Stimulate; Inhibit

Answer

Inhibit; Inhibit

Question 5

The use of succinylcholine is not contraindicated in which of the following conditions?

Accepted Answer

Hepatic failure

Answer

Tetanus

Answer

Closed head injury

Answer

Cerebral stroke

Question 6

Therapeutic use of acetylcholine is not possible because it is -

Accepted Answer

Rapidly degraded

Answer

Highly protein bound

Answer

Rapidly excreted

Answer

Orally ineffective

Question 7

Botulinum toxin mimics which class of drugs?

Accepted Answer

Anticholinergics

Answer

Cholinergics

Answer

Adrenergics

Answer

Antiadrenergics

Question 8

Which of the following is an example of a long-acting neuromuscular blocker?

Accepted Answer

Pancuronium

Answer

Rocuronium

Answer

Vecuronium

Answer

Atracurium

Question 9

Vasomotor reversal of Dale is demonstrated by

Accepted Answer

Fall in blood pressure by adrenaline pretreated with phentolamine

Answer

Fall in blood pressure by high dose intravenous Acetylcholine

Answer

Increase in blood pressure following administration of IV propranolol

Answer

Fall in blood pressure by a ganglionic blocker

Question 10

Which of the following drugs exhibits the phenomenon described?

Accepted Answer

Ephedrine

Answer

Epinephrine

Answer

Dopamine

Answer

Isoprenaline

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?